Back to results
US 2024/0293356 A1Published application
Cannabinoid Formulations
AssigneeEndocanna Health, Inc.
InventorsLen May, Eric Kaufman
Life of this patent
Estimating the term…
Abstract
The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.
Claims18
A formulation comprising:
- a cannabidiol (CBD) and a tetrahydrocannabinol (THC), wherein the formulation has a CBD:THC ratio from about 50:1 to about 1:50;
- a primary terpene;
- and a secondary terpene.
Dependencies are inferred from the claim text.